Onesource Specialty Pharma (ONESOURCE.NS) Stock Price
Onesource Specialty Pharma Price
Revenue has compounded at 510.9% per year over the past 2 years to 14.45 B INR. Onesource Specialty Pharma's net margin stands at -1.2%, up from -2,066.0% several years earlier. Analysts set a median price target of 2,153.22 INR, implying 41.7% above the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 36% above its 52-week low.
Onesource Specialty Pharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Onesource Specialty Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Onesource Specialty Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Onesource Specialty Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Onesource Specialty Pharma Price |
|---|---|
| 8/31/2026 | 1,519.10 INR |
| 8/28/2026 | 1,532.20 INR |
| 8/27/2026 | 1,519.70 INR |
| 8/26/2026 | 1,483.60 INR |
| 8/25/2026 | 1,516.10 INR |
| 8/24/2026 | 1,531.80 INR |
| 8/21/2026 | 1,535.00 INR |
| 8/20/2026 | 1,534.50 INR |
| 8/19/2026 | 1,532.00 INR |
| 8/17/2026 | 1,558.20 INR |
| 8/14/2026 | 1,559.20 INR |
| 8/13/2026 | 1,571.30 INR |
| 8/12/2026 | 1,578.30 INR |
| 8/10/2026 | 1,575.40 INR |
| 8/7/2026 | 1,576.00 INR |
| 8/6/2026 | 1,557.10 INR |
| 8/5/2026 | 1,553.70 INR |
| 8/4/2026 | 1,536.90 INR |
| 7/31/2026 | 1,619.70 INR |
| 7/30/2026 | 1,729.90 INR |
| 7/29/2026 | 1,749.70 INR |
| 7/28/2026 | 1,685.40 INR |
| 7/27/2026 | 1,688.90 INR |
| 7/24/2026 | 1,653.90 INR |
| 7/23/2026 | 1,645.20 INR |
| 7/22/2026 | 1,671.50 INR |
| 7/21/2026 | 1,651.20 INR |
| 7/20/2026 | 1,693.90 INR |
| 7/17/2026 | 1,640.60 INR |
| 7/15/2026 | 1,640.00 INR |
Onesource Specialty Pharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Onesource Specialty Pharma Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB INR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB INR |
| EBITB INR |
| EBIT MARGIN% |
| NET INCOMEB INR |
| NET INCOME GROWTH% |
| SHARESM |
| 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|
| 0.39 | 1.72 | 14.45 | 13.41 | 22.56 | 34.10 | 29.77 |
| – | 344.19 | 740.49 | -7.16 | 68.18 | 51.16 | -12.70 |
| -4.39 | 47.24 | 67.39 | 67.39 | 67.39 | 67.39 | 67.39 |
| -0.02 | 0.81 | 9.74 | 9.04 | 15.20 | 22.98 | 20.06 |
| -2.16 | -1.58 | 1.94 | 0.48 | 6.62 | 12.32 | 9.08 |
| -559.17 | -91.97 | 13.46 | 3.60 | 29.34 | 36.14 | 30.50 |
| -8.00 | -3.91 | -0.18 | -0.32 | 4.14 | 8.65 | 6.07 |
| – | -51.10 | -95.42 | 80.45 | -1,381.73 | 109.01 | -29.80 |
| 114.44 | 114.44 | 110.40 | 110.40 | 110.40 | 110.40 | 110.40 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Onesource Specialty Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Onesource Specialty Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Onesource Specialty Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Onesource Specialty Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Onesource Specialty Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Onesource Specialty Pharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Onesource Specialty Pharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Onesource Specialty Pharma business model & stock analysis
Onesource Specialty Pharma Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Onesource Specialty Pharma historical P/E ratio, EBIT multiple, and P/S ratio
Onesource Specialty Pharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Onesource Specialty Pharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Onesource Specialty Pharma forecasts and price targets in September 2026
Analyst Price Targets 2026Onesource Specialty Pharma shareholder structure
| % | Name |
|---|---|
5.33670% | |
2.34026% | |
1.63672% | |
1.28929% | |
0.82955% | |
0.70582% |
Onesource Specialty Pharma Beneficial Ownership Filings (SEC 13D/G)
Onesource Specialty Pharma Executives and Management Board
12 members · avg. age 60 · 20 % women
Neeraj Sharma (52)
Managing Director
2.67 M INR
Management
Ms. Allada Trisha
Compliance Officer, Company Secretary
Mr. Anurag Bhagania
Chief Financial Officer
Mr. Bernhard Bernhard
Chief Quality Officer
Board of Directors
Pudhucode Kannan (50)
Whole-Time Director · since 2021
Mr. Bhushan Bopardikar (37)
Director
Arun Pillai (62)
Director (Promoter)
Mr. Bharat Shah (76)
Director
Mr. Deepak Vaidya (78)
Independent Director
Dr. Claudio Albrecht (65)
Additional Non-Executive Independent Director
Frequently asked questions about Onesource Specialty Pharma
Analysts currently set an average price target of 2,094.06 INR for the Onesource Specialty Pharma stock (median: 2,153.22 INR), implying +32.9 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Onesource Specialty Pharma stock: 6 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Onesource Specialty Pharma to generate revenue of 13.41 B INR and earnings per share of -2.93 INR.
Converted at the current exchange rate, the Onesource Specialty Pharma share trades at 13.84 EUR (1,519.10 INR).
No history available for Onesource Specialty Pharma.
The expected revenue of Onesource Specialty Pharma is 13.41 B INR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Onesource Specialty Pharma is -323.80 M INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Onesource Specialty Pharma is currently -517.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Onesource Specialty Pharma stock.
The price-to-sales ratio (P/S) of Onesource Specialty Pharma is currently 12.50. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Onesource Specialty Pharma stock.
The Eulerpool Quality Score for Onesource Specialty Pharma is 2/10.
The ISIN of Onesource Specialty Pharma is INE013P01021. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Onesource Specialty Pharma is ONESOURCE.NS. The ticker symbol is used to trade Onesource Specialty Pharma shares on the stock exchange.
Onesource Specialty Pharma paid dividends every year for the past 0 years.
Onesource Specialty Pharma is assigned to the 'Health' sector.
The dividends of Onesource Specialty Pharma are distributed in INR.
Onesource Specialty Pharma stock
Onesource Specialty Pharma Peer Group
All fundamentals and in-depth analysis of Onesource Specialty Pharma
Our stock analysis for Onesource Specialty Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Onesource Specialty Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.